超说明书使用利妥昔单抗与获批的复发缓解型多发性硬化疾病修饰治疗相比的真实世界医疗费用节省与复发率降低:一项全国性成本效果研究
这项基于瑞典登记数据的队列研究纳入5924例18-65岁复发缓解型多发性硬化患者,比较利妥昔单抗与那他珠单抗、芬戈莫德、富马酸二甲酯的成本效果。
要点
- 利妥昔单抗组5年内平均避免0.12-0.22次复发。
- 作者认为可考虑超说明书低剂量利妥昔单抗用于多发性硬化患者。
核心结论
- 利妥昔单抗的成本效果优于获批的多发性硬化替代治疗。
- 作者认为可考虑超说明书低剂量利妥昔单抗用于多发性硬化患者,并可能减少治疗障碍,尤其是在资源有限的环境中。
研究设计与样本
- 基于登记的队列研究,纳入2010年1月至2016年7月期间开始利妥昔单抗、那他珠单抗、芬戈莫德或富马酸二甲酯治疗、随访至2021年7月的18-65岁瑞典复发缓解型多发性硬化居民,共5924例。
主要发现
- 超说明书利妥昔单抗与更少的复发相关,每开始一种治疗5年内平均避免0.12-0.22次复发。
- 结果对折扣和就诊定价的变化稳健,成本节省的主要驱动因素是索引药物本身的价格。
临床怎么用
- 作者认为可考虑超说明书低剂量利妥昔单抗用于多发性硬化患者,并可能减少治疗障碍,尤其是在资源有限的环境中。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Although off-label use of rituximab is a common alternative to disease-modifying therapies (DMTs) approved for multiple sclerosis (MS) in several countries, the impact of this on treatment cost-effectiveness is not well known. METHODS: We evaluated the relative cost-effectiveness of rituximab and MS-approved DMTs in a register-based cohort study of Swedish residents with relapsing-remitting MS, aged 18-65 years, starting treatment with rituximab, natalizumab, fingolimod, or dimethyl fumarate between January 2010 and July 2016, and followed through July 2021 (n = 5,924). By linking the population-based Swedish MS register to several Swedish health care and demographic registers, we estimated health care costs in relation to number of relapses, over 5 years from treatment start. Differences between treatments were estimated in inverse probability of treatment-weighted regression models, adjusting for a broad range of potential confounders covering demographics, medical history, and MS-related clinical characteristics. RESULTS: Off-label rituximab was associated with both lower total health care costs (mean cost savings ranged $35,000-$66,000 vs. each approved DMT), and fewer relapses (mean number of prevented relapses ranged 0.12-0.22), per started therapy over 5 years. Results were robust to variations in discounting and pricing of health care visits, with the main driver of cost-savings being the price of the index drug itself. INTERPRETATION: The cost-effectiveness of rituximab dominated the MS-approved alternatives. Off-label, low-dose rituximab should be considered for persons with MS and could reduce barriers to treatment, especially in resource-limited settings. ANN NEUROL 2024;95:1099-1111.
引用
- Alping P, Neovius M, Piehl F, et al. Real-World Healthcare Cost Savings and Reduced Relapse Rate with Off-Label Rituximab versus Disease-Modifying Treatments Approved for Relapsing-Remitting Multiple Sclerosis: A Nationwide Cost-Effectiveness Study. Ann Neurol. 2024. PMID: 38529711. doi:10.1002/ana.26914
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。